Inogen has demonstrated a disciplined financial recovery, marked by stabilized quarterly revenues, improved adjusted EBITDA profitability, and tighter control over operating expenses. While domestic U.S. sales and rental channels have encountered retail pressures, the company's international business division has posted consecutive quarters of robust double-digit growth. Supported by a solid balance sheet carrying no long-term debt, Inogen continues to allocate capital strategically toward global product expansion, innovative respiratory device rollouts, and operational efficiencies.